Head-to-Head Comparison of Treatments for Multiple Food Allergies: Omalizumab Comes Out Ahead, but the Key Is Not Just the Amount Tolerated
A U.S. randomized trial found that participants who continued the anti-IgE antibody were more likely to pass high-dose challenges with three foods; however, the difference was driven mainly by more adverse reactions and withdrawals with oral immunotherapy, rather than a large disparity in efficacy among those who completed treatment.